We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

120 hedge funds and large institutions have $1.24B invested in Zentalis Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,086% more call options, than puts

Call options by funds: $17.1M | Put options by funds: $536K

33% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 33

1.84% more ownership

Funds ownership: 113.58% → 115.41% (+1.8%)

12% less funds holding

Funds holding: 137 → 120 (-17)

23% less capital invested

Capital invested by funds: $1.61B → $1.24B (-$371M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

44% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 36

Holders
120
Holders Change
-17
Holders Change %
-12.41%
% of All Funds
1.75%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
20
Increased
44
Reduced
33
Closed
36
Calls
$17.1M
Puts
$536K
Net Calls
+$16.5M
Net Calls Change
+$12.6M

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$54.7M
2
State Street
State Street
Massachusetts
+$25M
3
Citadel Advisors
Citadel Advisors
Florida
+$22.3M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$12.3M
5
Morgan Stanley
Morgan Stanley
New York
+$9.82M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$42.1M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$27M
3
SI
Sofinnova Investments
California
-$24.3M
4
FLAM
First Light Asset Management
Minnesota
-$17M
5
CAM
Cormorant Asset Management
Massachusetts
-$14M
Name Holding Trade Value Shares
Change 		Change in
Stake
Verition Fund Management
26
Verition Fund Management
Connecticut
$5.22M -$2.81M -192,742 -36%
Renaissance Technologies
27
Renaissance Technologies
New York
$4.69M +$348K +23,840 +8%
Goldman Sachs
28
Goldman Sachs
New York
$4.44M +$1.02M +69,620 +31%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$4.4M +$701K +48,027 +20%
IHAM
30
Integral Health Asset Management
New York
$3.79M -$2.92M -200,000 -44%
Barclays
31
Barclays
United Kingdom
$3.33M +$1.59M +108,701 +98%
Ensign Peak Advisors
32
Ensign Peak Advisors
Utah
$2.95M – – –
TD Asset Management
33
TD Asset Management
Ontario, Canada
$2.88M +$137K +9,400 +5%
MC
34
Mayo Clinic
Minnesota
$2.84M – – –
Voloridge Investment Management
35
Voloridge Investment Management
Florida
$2.66M +$2.56M +175,537 New
Norges Bank
36
Norges Bank
Norway
$2.49M – – –
SG Americas Securities
37
SG Americas Securities
New York
$2.31M +$91.2K +6,252 +4%
VOYA Investment Management
38
VOYA Investment Management
Georgia
$2.26M +$565K +38,753 +35%
Citigroup
39
Citigroup
New York
$2.21M +$886K +60,713 +71%
N
40
Nuveen
North Carolina
$1.97M +$31.2K +2,138 +2%
CM
41
Caption Management
Oklahoma
$1.9M +$1.83M +125,727 New
Manulife (Manufacturers Life Insurance)
42
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.77M +$386K +26,491 +29%
Swiss National Bank
43
Swiss National Bank
Switzerland
$1.48M -$160K -11,000 -10%
JP Morgan Chase
44
JP Morgan Chase
New York
$1.42M -$124K -8,481 -8%
Marshall Wace
45
Marshall Wace
United Kingdom
$1.35M -$2.65M -181,826 -67%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$1.22M -$1.02K -70 -0.1%
Wellington Management Group
47
Wellington Management Group
Massachusetts
$1.04M -$27M -1,848,314 -96%
UBS AM
48
UBS AM
Illinois
$957K -$2.71M -185,938 -75%
PA
49
Profund Advisors
Maryland
$882K +$351K +24,063 +70%
AllianceBernstein
50
AllianceBernstein
Tennessee
$874K – – –
1
2
3 4 5

ZNTL Hedge Fund Activity: Q4 2023 in Review

120 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2023, worth a combined $1.24B — down 23% from $1.61B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of ZNTL and 20 opened new positions — a net loss of 16 holders — while 33 trimmed existing stakes and 44 added.

The largest buyer was Eventide Asset Management, adding an estimated $54.7M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $42.1M sold.

  • 120 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2023, down from 137 in Q3 2023.
  • Funds reported $1.24B of Zentalis Pharmaceuticals stock for Q4 2023, down 23% quarter-over-quarter.
  • 20 funds opened new Zentalis Pharmaceuticals positions in Q4 2023 and 36 closed out, a net change of -16 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q4 2023 was Eventide Asset Management, an estimated $54.7M added.
  • The largest Zentalis Pharmaceuticals seller in Q4 2023 was Avidity Partners Management, an estimated $42.1M sold.

Based on aggregated 13F filings for Q4 2023.